STOMAZE
MEFENAMIC ACID 250 MG + DROTAVERINE 80 MG TABS
Brand: STOMAZE
MRP
₹1050/-
Packaging
10*10 A/A
Form
ANALGESIC/NSAID'S
Description & Usage
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs are pharmaceutical tablets that are manufactured by combining two ingredients, namely Mefenamic Acid and Drotaverine. They have a significant place in general medicine and pain management products. This formulation (250 mg Mefenamic Acid and 80 mg Drotaverine) presents a professional identity to the product and it holds importance to any pharmaceutical company dealing in tablets as part of their product range.
Companies engaged in the PCD pharma franchise sector, contract manufacturing, branded marketing of medicines and other pharmaceutical distributors and suppliers often list Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs in their product range. Its availability in the dosage form of tablet enhances its ease in packing, storage, distribution and marketing. It is a highly portable formulation that facilitates it's movement through various pharmaceutical channels and with standard manufacturing quality, attractive packaging and guaranteed availability it becomes an invaluable part of the overall portfolio of a professional pharma concern.
Composition Profile And Value of Tablet Formulation
Each tablet of this formulation contains Mefenamic Acid (250 mg) along with Drotaverine (80 mg) as the prime composition. Mefenamic Acid is an established, well-known pharmaceutical agent within the pain management segment while Drotaverine further elevates the potential and value of the entire product profile. Both these ingredients jointly create an excellent, highly market-worthy tablet formulation for the pharmaceutical sector.
This tablet formulation would be prepared with appropriate pharmaceutical-grade excipients, which would provide adequate hardness, shape, shelf-life, stability and disintegrating ability to the tablet, along with ensuring even distribution of active ingredients in each of the tablets to guarantee product uniformity from batch to batch and thereby increase product value.
Manufacturing and Processing Standards
The formulation would require rigorous quality controls and hygienic standards at the manufacturing unit. Reliable manufacturers would employ quality raw materials, advanced production machinery and controlled manufacturing practices so as to retain the efficacy of the composition, and uphold the quality, strength, stability and uniform composition of every tablet. Each stage in the manufacturing process would be carried out under qualified technical assistance to uphold a standard pharma product quality.
Quality control would be carried out at various stages right from raw material analysis through to granules examination and blending checks followed by tablet compression, and finally final finished product analysis. For a dual combination such as Mefenamic Acid 250 mg, Drotaverine 80 mg, even distribution of active ingredients is crucial, thus thorough blending operations are of paramount importance, while adhering to standard GMP rules for pharmaceuticals ensures uniform quality for product batches and increased marketability in the pharmaceutical sector and build trust with the various channels i.e. Wholesalers, retailers, and franchisees etc.
Packaging, Labelling and Branding Aspects
Packaging also contributes greatly towards the preservation of the formulation along with making it presentable as an entity within the competitive pharma market. Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs could be made available in attractive blister packaging, alu-alu, or strip packaging formats depending on the company's preference. Proper packaging is essential to maintain the formulation against light, moisture and other environmental hazards and thereby prolong it's life.
Every package and product label should clearly indicate brand name, salts (Mefenamic Acid and Drotaverine), composition strength (250mg, 80mg), tablet count, product batch number, manufactured date, expiry date, MRP, dosage information and company name along with it's address and license details. Attractive branding and neat presentation certainly make any product stand out and portray professionalism and trust within it's sector. Attractive packaging helps to achieve a high market recognition and product value, thus making it a viable candidate for promotional strategies of pharmaceutical companies.
Market Demand and Importance
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs are in good demand in the pharmaceutical sector as a component often featured as a general medicine or pain management product for tablet based remedies. This product can help in the expansion of any firm's tablet section given the strong market acceptance that the formulation stands to gain from it's composition and relevance in the relevant medical segments. The dual composition inherently adds significant value to this product range.
The market relevance and acceptance of this formulation can benefit wholesalers, retailers, and distributors as well as PCD franchise companies immensely in strengthening their business operations with a standard product that enjoys widespread use. A lot of pharma companies consider Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs to be a beneficial addition to their overall product mix of tablet, capsules, syrups, suspensions, injections and nutraceuticals, hence to improve market penetration it is very useful.
With robust quality, efficient packaging and guaranteed supply the formulation can add trust to the company within their respective channels in the market and it will certainly help both established as well as emerging businesses in targeting the pain management and general medicine markets.
PCD Pharma Franchise Aspect
The product Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs holds excellent prospects in the PCD Pharma Franchise segment, being a medicine category with regular market requirement, it is suitable for wide promotion with efficient promotional strategies which can be provided to the PCD franchise partners (like visual aids, product cards, reminder cards, prescription pads, MR bags and product literature etc.). This product, when included in the PCD franchise list would be one which the distributors would have no qualms about promoting, given it's consistent market value and usage. Pharma companies aiming at developing the PCD pharma franchise network would consider Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs, to provide their franchisees with a competitive and reliable product backed with competitive quality, good packaging, appropriate promotional support, monopoly rights where applicable, as well as time bound and timely distribution. Its double combination aspect along with its tablet format and overall market appeal make it an ideal product to consider for any business focusing on expanding their general medicine and pain management market share.
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs are pharmaceutical tablets that are manufactured by combining two ingredients, namely Mefenamic Acid and Drotaverine. They have a significant place in general medicine and pain management products. This formulation (250 mg Mefenamic Acid and 80 mg Drotaverine) presents a professional identity to the product and it holds importance to any pharmaceutical company dealing in tablets as part of their product range.
Companies engaged in the PCD pharma franchise sector, contract manufacturing, branded marketing of medicines and other pharmaceutical distributors and suppliers often list Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs in their product range. Its availability in the dosage form of tablet enhances its ease in packing, storage, distribution and marketing. It is a highly portable formulation that facilitates it's movement through various pharmaceutical channels and with standard manufacturing quality, attractive packaging and guaranteed availability it becomes an invaluable part of the overall portfolio of a professional pharma concern.
Composition Profile And Value of Tablet Formulation
Each tablet of this formulation contains Mefenamic Acid (250 mg) along with Drotaverine (80 mg) as the prime composition. Mefenamic Acid is an established, well-known pharmaceutical agent within the pain management segment while Drotaverine further elevates the potential and value of the entire product profile. Both these ingredients jointly create an excellent, highly market-worthy tablet formulation for the pharmaceutical sector.
This tablet formulation would be prepared with appropriate pharmaceutical-grade excipients, which would provide adequate hardness, shape, shelf-life, stability and disintegrating ability to the tablet, along with ensuring even distribution of active ingredients in each of the tablets to guarantee product uniformity from batch to batch and thereby increase product value.
Manufacturing and Processing Standards
The formulation would require rigorous quality controls and hygienic standards at the manufacturing unit. Reliable manufacturers would employ quality raw materials, advanced production machinery and controlled manufacturing practices so as to retain the efficacy of the composition, and uphold the quality, strength, stability and uniform composition of every tablet. Each stage in the manufacturing process would be carried out under qualified technical assistance to uphold a standard pharma product quality.
Quality control would be carried out at various stages right from raw material analysis through to granules examination and blending checks followed by tablet compression, and finally final finished product analysis. For a dual combination such as Mefenamic Acid 250 mg, Drotaverine 80 mg, even distribution of active ingredients is crucial, thus thorough blending operations are of paramount importance, while adhering to standard GMP rules for pharmaceuticals ensures uniform quality for product batches and increased marketability in the pharmaceutical sector and build trust with the various channels i.e. Wholesalers, retailers, and franchisees etc.
Packaging, Labelling and Branding Aspects
Packaging also contributes greatly towards the preservation of the formulation along with making it presentable as an entity within the competitive pharma market. Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs could be made available in attractive blister packaging, alu-alu, or strip packaging formats depending on the company's preference. Proper packaging is essential to maintain the formulation against light, moisture and other environmental hazards and thereby prolong it's life.
Every package and product label should clearly indicate brand name, salts (Mefenamic Acid and Drotaverine), composition strength (250mg, 80mg), tablet count, product batch number, manufactured date, expiry date, MRP, dosage information and company name along with it's address and license details. Attractive branding and neat presentation certainly make any product stand out and portray professionalism and trust within it's sector. Attractive packaging helps to achieve a high market recognition and product value, thus making it a viable candidate for promotional strategies of pharmaceutical companies.
Market Demand and Importance
Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs are in good demand in the pharmaceutical sector as a component often featured as a general medicine or pain management product for tablet based remedies. This product can help in the expansion of any firm's tablet section given the strong market acceptance that the formulation stands to gain from it's composition and relevance in the relevant medical segments. The dual composition inherently adds significant value to this product range.
The market relevance and acceptance of this formulation can benefit wholesalers, retailers, and distributors as well as PCD franchise companies immensely in strengthening their business operations with a standard product that enjoys widespread use. A lot of pharma companies consider Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs to be a beneficial addition to their overall product mix of tablet, capsules, syrups, suspensions, injections and nutraceuticals, hence to improve market penetration it is very useful.
With robust quality, efficient packaging and guaranteed supply the formulation can add trust to the company within their respective channels in the market and it will certainly help both established as well as emerging businesses in targeting the pain management and general medicine markets.
PCD Pharma Franchise Aspect
The product Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs holds excellent prospects in the PCD Pharma Franchise segment, being a medicine category with regular market requirement, it is suitable for wide promotion with efficient promotional strategies which can be provided to the PCD franchise partners (like visual aids, product cards, reminder cards, prescription pads, MR bags and product literature etc.). This product, when included in the PCD franchise list would be one which the distributors would have no qualms about promoting, given it's consistent market value and usage. Pharma companies aiming at developing the PCD pharma franchise network would consider Mefenamic Acid 250 MG, Drotaverine 80 MG Tabs, to provide their franchisees with a competitive and reliable product backed with competitive quality, good packaging, appropriate promotional support, monopoly rights where applicable, as well as time bound and timely distribution. Its double combination aspect along with its tablet format and overall market appeal make it an ideal product to consider for any business focusing on expanding their general medicine and pain management market share.